RMH Neuroscience Foundation dementia researchers have been involved in the global commercial trial ‘TRAILBLAZER: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease’ since start-up in 2021.
The drug has been found to slow the progress of Alzheimer's disease by clearing proteins in the brain, and now, has been approved by the Therapeutic Goods Administration (TGA) for use in Australia.
Eli Lilly, the pharmaceutical company that makes the drug, said an application for Donanemab to be listed on the Pharmaceutical Benefits Scheme (PBS) would be reviewed by the advisory committee in July.
Read the full story:
ABC News | Specialist Reporting 22/05/25
Photo: Evidence of Alzheimer’s disease on PET scans.
Photographer: Brian Snyder/Reuters. Source: The Guardian.